Log in

Lantheus Stock Price, News & Analysis (NASDAQ:LNTH)

$18.86
-0.04 (-0.21 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
$18.69
Now: $18.86
$19.07
50-Day Range
$18.40
MA: $22.37
$26.79
52-Week Range
$12.59
Now: $18.86
$29.80
Volume181,650 shs
Average Volume378,520 shs
Market Capitalization$732.15 million
P/E Ratio20.06
Dividend YieldN/A
Beta1.51
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures. Read More…

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LNTH
CUSIPN/A
Phone978-671-8001

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$343.37 million
Cash Flow$1.35 per share
Book Value$1.85 per share

Profitability

Net Income$40.51 million

Miscellaneous

Employees488
Market Cap$732.15 million
Next Earnings Date10/29/2019 (Estimated)
OptionableOptionable

Receive LNTH News and Ratings via Email

Sign-up to receive the latest news and ratings for LNTH and its competitors with MarketBeat's FREE daily newsletter.


Lantheus (NASDAQ:LNTH) Frequently Asked Questions

What is Lantheus' stock symbol?

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

How were Lantheus' earnings last quarter?

Lantheus Holdings Inc (NASDAQ:LNTH) issued its quarterly earnings results on Thursday, July, 25th. The medical equipment provider reported $0.27 earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of $0.27. The medical equipment provider earned $85.70 million during the quarter, compared to analyst estimates of $88.72 million. Lantheus had a net margin of 11.20% and a return on equity of 51.08%. Lantheus's quarterly revenue was up .1% compared to the same quarter last year. During the same quarter last year, the business posted $0.25 EPS. View Lantheus' Earnings History.

When is Lantheus' next earnings date?

Lantheus is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for Lantheus.

What guidance has Lantheus issued on next quarter's earnings?

Lantheus issued an update on its FY19 earnings guidance on Thursday, July, 25th. The company provided earnings per share (EPS) guidance of $1.09-1.12 for the period, compared to the Thomson Reuters consensus estimate of $1.12. The company issued revenue guidance of $346-350 million, compared to the consensus revenue estimate of $360.07 million.

What is the consensus analysts' recommendation for Lantheus?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Lantheus.

Has Lantheus been receiving favorable news coverage?

News coverage about LNTH stock has been trending somewhat negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Lantheus earned a news sentiment score of -1.5 on InfoTrie's scale. They also assigned news articles about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Lantheus.

Are investors shorting Lantheus?

Lantheus saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 1,410,000 shares, an increase of 6.8% from the August 30th total of 1,320,000 shares. Based on an average daily trading volume, of 432,500 shares, the days-to-cover ratio is currently 3.3 days. Approximately 3.7% of the company's shares are sold short. View Lantheus' Current Options Chain.

Who are some of Lantheus' key competitors?

What other stocks do shareholders of Lantheus own?

Who are Lantheus' key executives?

Lantheus' management team includes the folowing people:
  • Ms. Mary Anne Heino, CEO, Pres & Director (Age 59)
  • Mr. Robert J. Marshall Jr., CFO & Treasurer (Age 52)
  • Mr. Michael P. Duffy, Sr. VP of Law & Public Policy, Gen. Counsel and Sec. (Age 58)
  • Dr. Cesare Orlandi, Chief Medical Officer (Age 69)
  • Mr. John J. Bolla, Chief Operating Officer (Age 49)

When did Lantheus IPO?

(LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

Who are Lantheus' major shareholders?

Lantheus' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (0.56%), Bowling Portfolio Management LLC (0.11%), State of Alaska Department of Revenue (0.08%), Envestnet Asset Management Inc. (0.06%) and Campbell & CO Investment Adviser LLC (0.04%). Company insiders that own Lantheus stock include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, John W Crowley, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Robert J Jr Marshall, Sam R Leno, Timothy G Healey and Tudor Brown. View Institutional Ownership Trends for Lantheus.

Which major investors are selling Lantheus stock?

LNTH stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Campbell & CO Investment Adviser LLC and Bowling Portfolio Management LLC. Company insiders that have sold Lantheus company stock in the last year include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, John J Bolla, Mary Anne Heino, Michael P Duffy, Robert J Jr Marshall, Sam R Leno and Tudor Brown. View Insider Buying and Selling for Lantheus.

Which major investors are buying Lantheus stock?

LNTH stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue and Envestnet Asset Management Inc.. View Insider Buying and Selling for Lantheus.

How do I buy shares of Lantheus?

Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Lantheus' stock price today?

One share of LNTH stock can currently be purchased for approximately $18.86.

How big of a company is Lantheus?

Lantheus has a market capitalization of $732.15 million and generates $343.37 million in revenue each year. The medical equipment provider earns $40.51 million in net income (profit) each year or $0.94 on an earnings per share basis. Lantheus employs 488 workers across the globe.View Additional Information About Lantheus.

What is Lantheus' official website?

The official website for Lantheus is http://www.lantheus.com/.

How can I contact Lantheus?

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected]


MarketBeat Community Rating for Lantheus (NASDAQ LNTH)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  250 (Vote Outperform)
Underperform Votes:  229 (Vote Underperform)
Total Votes:  479
MarketBeat's community ratings are surveys of what our community members think about Lantheus and other stocks. Vote "Outperform" if you believe LNTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LNTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel